The Antihypertensive Effect of Lisinopril Compared to Atenolol in Patients with Mild to Moderate Hypertension

Bolzano, K; Arriaga, J; Bernal, Rodolfo; Bernardes, Hélio; Calderón, Javier; deBruyn, Jennifer; Dienstl, F; Drayer, Jan I.M.; Goodfriend, Theodore L.; Gross, W. B.; Guthrie, Gordon P.; Holwerda, Nicholas J.; Klein, W.; Lr, Krakoff; Liebau, H.; Oparil, S.; Reams, Garry P.; Reed, William; Safar, M; Schubotz, R; Seedat, Y K; Thind, Gurdarshan S.; Veriava, Yosuf; Wollam, Gary L.; Woods, James W.; Zusman, Randall M.

doi:10.1097/00005344-198700003-00011

Cited by 46 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lisinopril effectively lowers blood pressure in patients with essential (Bolzano et al, 1987;Morlin etal., 1987;Pool etal., 1987;Zachariah et al, 1987) and renovascular (Donohoe et al, 1987;Fyhrquist et al, 1987) hypertension, and improves signs and symptoms in congestive heart failure (Chalmers et al, 1987;Powers et al, 1987). Clinical experience to date indicates that lisinopril is safe and well tolerated (Rush & Merrill, 1987).…”

Section: Introductionmentioning

confidence: 99%

Lisinopril dose‐response relationship in essential hypertension.

Gómez

Cirillo

Sromovsky

et al. 1989

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 This was a multicentre, double-blind, parallel study in 216 patients with mild to moderate (supine diastolic blood pressure = 95-115 mm Hg) essential hypertension. 2 After a 4-week placebo washout, patients were randomized to placebo or lisinopril 1.25, 5, 20 or 80 mg once daily for 6 consecutive weeks. Supine and erect blood pressure was measured 24 h postdose at the end of weeks -2, 0, 2, 4, and 6. 3 There was a linear dose-response relationship for both supine and erect blood pressure. Diastolic blood pressure reductions in the lisinopril 20 and 80 mg day-' groups were significantly greater than in the placebo or lisinopril 1.25 and 5 mg day-' groups. 4 Lisinopril, at doses up to 80 mg day-', was well tolerated.

show abstract

Section: Introductionmentioning

confidence: 99%

Lisinopril dose‐response relationship in essential hypertension.

Gómez

Cirillo

Sromovsky

et al. 1989

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Lisinopril effectively reduces blood pressure in patients with essential (Pool et al, 1987;Bolzano et al, 1987;Morlin et al, 1987;Zachariah et al, 1987) and renovascular (Fyhrquist et al, 1987;Donohoe et al, 1987) hypertension, and improves signs, symptoms and exercise capacity in congestive heart failure (Powers et al, 1987;Chalmers et al, 1987). Experience to date indicates that lisinopril is well tolerated, and has a good safety profile (Rush & Merrill, 1987).…”

Section: Introductionmentioning

confidence: 99%

Lisinopril: dose‐peak effect relationship in essential hypertension.

Cirillo

Gómez

Salonen

et al. 1988

Brit J Clinical Pharma

View full text Add to dashboard Cite

3 Lisinopril 10 and 20 mg day-' produced similar peak antihypertensive effects which were greater than that produced by 2.5 mg day-1, but less than that of 80 mg day-'. If the incidence of first-dose symptomatic hypotension is related to the peak effect, then an initial lisinopril dose of 20 mg should not pose any greater risk than a 10 mg dose. 4 The magnitude of antihypertensive response at 24 h postdrug appeared to be dose related across the 2.5 to 80 mg day-' range.

show abstract

“…In the Bol- [ 16]. zano et al study [12], although both lisinopril and atenolol reduced sitting diastolic blood pressure to a similar extent, lisinopril produced a more significant (p < 0.01) re duction in sitting systolic blood pressure than atenolol. Five patients on lisinopril and four on atenolol developed skin rashes dur ing the first two weeks of treatment.…”

Section: Comparison Of Ace Inhibitors With Other Antihypertensive Andmentioning

confidence: 89%

“…More recently, the newer ACE inhibitor lisinopril has been compared with atenolol and metoprolol in several studies [11,12]. While the overall rates of adverse events were similar for both lisinopril and atenolol, chest pain was more frequently reported with atenolol (3.4 vs 0.3%, p < 0.01).…”

Section: Comparison Of Ace Inhibitors With Other Antihypertensive Andmentioning

confidence: 99%

“…Enalapril, a nonsulfhydryl compound and a longer-acting agent than captopril, was the next ACE inhibitor to be developed [7][8][9][10]. More recently, lisinopril, a lysine derivative of enalapril, was introduced [11][12][13][14], Both captopril and enalapril were thoroughly re viewed for safety prior to regulatory approv al, and since their introduction have re ceived intensive study using postmarketing surveillance [11][12][13][14], However, research continues into the development of ACE in hibitors that exhibit the same high degree of efficacy but with fewer and less severe ad verse events. Quinapril, a second-generation ACE inhibitor which, like enalapril and lis inopril, does not have a sulfhydryl group, has been studied in over 2,000 patients [15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Safety of ACE Inhibitors for the Treatment of Hypertension and Congestive Heart Failure

Frank¹

1989

Cardiology

View full text Add to dashboard Cite

Angiotensin-converting enzyme (ACE) inhibitors are being increasingly prescribed for the treatment of hypertension and heart failure. Not only are they efficacious but the incidence of serious adverse events with ACE inhibitors is similar to that with placebo. ‘First-dose hypotension’ mainly affects the renin-dependent patient. Neutropenia and agranulocytosis have been reported rarely for the nonsulfhydryl compounds. Comparative safety data are provided for captopril, enalapril, and quinapril, a new nonsulfhydryl ACE inhibitor that has been investigated extensively in over 2,000 patients. Results show that the proportion of patients reporting associated adverse events was lower with quinapril (11 %) than with captopril (17%) or enalapril (15%). Similarly, there was a lower proportion of patients withdrawn due to adverse events with quinapril.

show abstract

The Antihypertensive Effect of Lisinopril Compared to Atenolol in Patients with Mild to Moderate Hypertension

Cited by 46 publications

References 0 publications

Lisinopril dose‐response relationship in essential hypertension.

Lisinopril dose‐response relationship in essential hypertension.

Lisinopril: dose‐peak effect relationship in essential hypertension.

The Safety of ACE Inhibitors for the Treatment of Hypertension and Congestive Heart Failure

Contact Info

Product

Resources

About